ChiCTR2000029765 is an ongoing Chinese RCT trial investigating tocilizumab, a monoclonal antibody blocking IL-6, which is considered to play an important role in the Cytokine release syndrome (CRS) caused by SARS-CoV-2 that may lead to death. Here, IL6 is linked to congenital rubella syndrome.